All High-Throughput Screening (HTS) articles – Page 10
-
WhitepaperCase Study: Target discovery for rheumatoid arthritis
Learn more about Euretos computational disease model and how it predicts many of the known drug targets for RA.
-
ArticleA Guide to DNA Damage Response and Innate Immunity
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
-
WhitepaperArticle: Tips and Tricks for Leveraging Advanced Flow Cytometry
Tips and tricks for fully leveraging Advanced Flow Cytometry.
-
WebinarAdvancing therapeutics targeting cytokines with functional cell-based assays
Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.
-
NewsTargets for pancreatic cancer treatment found
Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.
-
NewsHow gene regulatory networks maintain FLT3-ITD mutated AML
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
-
News
Investigating the genetic changes of the DDX3X gene
Using saturation genome editing, researchers have created a map of disease-causing mutations for neurodevelopmental disorders and cancer.
-
ReportBeyond the lab: screening
Register to access the very latest research, insights and innovations including CRISPR activation screening, AI-aided screening and using nanofibrillar cellulose hydrogels.
-
WhitepaperHandbook: Advanced flow cytometry handbook
Don’t miss out on the easier way to do flow cytometry. Learn how to bring speed, throughput, multiplexing and miniaturization, to your bench.
-
WebinarBiophysics in kinase drug discovery: FBS to PROTAC® ternary complex characterisation
Watch this webinar to learn how biophysics can be used in different cascade strategies where the goal is to identify and characterise fragments, compounds or active degraders targeting PIM3 kinase.
-
WebinarComplete aggregate and particle characterisation of protein, gene and cell therapies
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
-
Whitepaperebook: Maximizing preclinical confidence in target efficacy and safety
This ebook outlines Euretos’ approach to target discovery and indication expansion. Whilst also discussing data-driven target selection.
-
WhitepaperGuide: Screening biologic candidates with nanoDSF
Read this guide about nanoDSF for high-resolution measurements of thermal stability parameters, common CQAs for biologics developability assessment.
-
NewsNew test promises better detection of elusive cervical cancers
Researchers have developed a novel test capable of detecting a form of cervical cancer that frequently eludes detection through traditional Pap tests.
-
WhitepaperInfographic: Biologics stability in early development
Stability attributes of biologic candidates are evaluated during early development workflows. Learn how to measure them with biophysical techniques.
-
WebinarTurning Plans into Reality: Real Examples of Custom Automation Projects
Watch our industry experts to learn about the tangible benefits and best practice of custom flow cytometry automation projects. You’ll discover how to reduce your challenges implementing tailored automation, controlling the quality of the data produced and improving the reliability of your data acquisition.
-
WebinarSH2 domains as a target class in cancer and inflammation
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
-
WebinarBridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics
The webinar will explore primary concerns in drug discovery development and why drugs fail.
-
News
Rare cause of hereditary cancer missed in younger patients
US investigators find that some cases of Lynch syndrome, the most common hereditary cancer condition, are missed in younger patients under current screening guidelines.
-
WhitepaperCase study: Mitochondrial toxicity in drug discovery and development
The Agilent Seahorse XF assay platform has opened new avenues for examining mitochondrial health in a timely and effective manner.